

Please type a sign (+) inside this box →

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

20/9T/T0
JC698 U.S.P.T.O.
01/16/02

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No. 1735.0610001/RWE/ALS

First Inventor Shailaja Kasibhatla

Title Methods of Identifying Potentially Therapeutically Selective and Effective Anti-Cancer Agents that are Inducers of Apoptosis

Express Mail Label No. 

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1101046548 PRO
01/16/02

- Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- Applicant claims small entity status.
See 37 CFR 1.27.
- Specification [Total Pages 39]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- Drawing(s) (35 U.S.C. 113) [Total Sheets 7]
- Oath or Declaration [Total Pages _____]
 - Newly executed (original or copy)
 - Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
- Application Data Sheet. See 37 CFR 1.76.
- CD-ROM or CD-R in duplicate, large table or Computer Program
(Appendix)
- Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - Computer Readable Form (CRF)
 - Specification Sequence Listing on:
 - CD-ROM or CD-R (2 copies), or
 - paper
 - Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- Assignment Papers (cover sheet & document(s))
- 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
- English Translation Document *(if applicable)*
- Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- Preliminary Amendment
- Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i) Applicant must attach form PTO/SB/35 or its equivalent
- Other: Authorization under 37 C.F.R. § 1.136(a)(3)
- Other: The name of the assignee is: Cytovia, Inc.

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

Continuation Divisional Continuation-in-Part (CIP)
Prior application information Examiner _____ of prior application No: _____ / _____
Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS


Customer Number or Bar Code Label

Customer No. 26111



or Correspondence address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX PLLC Attorneys at Law		
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	

NAME (Print/Type)	Aaron L. Schwartz	Registration No. (Agent)	48,181
SIGNATURE			
Date	1/16/02		

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

01/16/02
JC698 U.S. PTO

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, NW • WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 • FACSIMILE (202) 371-2540 • www.skgf.com

ROBERT GREENE STERNE JOHN M COVERT
EDWARD J KESSLER LINDA E ALCORN
JORGE A GOLDSTEIN ROBERT C MILLONIG
SAMUEL L FOX** MICHAEL V MESSINGER
DAVID K S CORNWELL JUDITH U KIM
ROBERT W ESMOND TIMOTHY J SHEA, JR
TRACY-GENE G DURKIN PATRICK E GARRETT
MICHELE A CIMBALA JEFFREY T HELVEY*
MICHAEL B RAY HEIDI L KRAUS
ROBERT E SOKOHL JEFFREY R KURIN
ERIC K STEFFE PATRICK D O'BRIEN
MICHAEL Q LEE LAWRENCE B BUGAISKY
STEVEN R LUDWIG CRYSTAL D SAYLES

EDWARD W YEE
ALBERT L FERRO*
DONALD R BANOWIT
PETER A JACKMAN
MOLLY A McCALL
TERESA U MEDLER
JEFFREY S WEAVER
KENDRICK P PATTERSON
DONALD J FEATHERSTONE
VINCENT L CAPUANO
JOHN A HARROUN*
ALBERT J. FASULO II*
ELDORA ELLISON FLOYD*

W RUSSELL SWINDELL
THOMAS C FIALA
BRIAN J DEL BUONO*
VIRGIL L BEASTON*
RYAN J STAMPER*
REGINALD D LUCAS*
THEODORE A WOOD
ELIZABETH J HAANES
BRUCE E CHALKER
JOSEPH S OSTROFF
KAREN R MARKOWICZ**
SUZANNE E ZISKA**
ANDREA J KAMAGE**

NANCY J LEITH**
JOSEPH M CONRAD, III**
DOUGLAS M WILSON**
ANN E SUMMERFIELD**
CYNTHIA M BOUCHEZ**
HELENE C CARLSON**
GABY L LONGSWORTH**
DUSTIN T JOHNSON**
MATTHEW J DOWD**
AARON L SCHWARTZ**

*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

January 16, 2002

WRITER'S DIRECT NUMBER:

(202) 371-2619

INTERNET ADDRESS:

SCHWARTZ@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
Appl. No. *To be assigned*; Filed: *Herewith*
For: **Methods of Identifying Potentially Therapeutically Selective and Effective Anti-Cancer Agents that are Inducers of Apoptosis**
Inventors: Kasibhatla *et al.*
Our Ref: 1735.0610001/RWE/ALS

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. PTO Utility Patent Application Transmittal Form (PTO/SB/05) (*in duplicate*);
2. U.S. Utility Patent Application entitled:

Methods of Identifying Potentially Therapeutically Selective and Effective Anti-Cancer Agents that are Inducers of Apoptosis

and naming as inventors:

Shailaja Kasibhatla
P. Sanjeeva Reddy
John A. Drewe

Commissioner for Patents
January 16, 2002
Page 2

the application consisting of:

- a. A specification containing:
 - i. 34 pages of description prior to the claims;
 - ii. 4 pages of claims (12 claims);
 - iii. a one (1) page abstract;
 - b. 7 sheets of drawings (Figures 1A-1B, 2A-2B, and 3-7);
 - c. Application Data Sheet;
3. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (*in duplicate*); and
 4. Two (2) return postcards.

The name of the assignee is Cytovia, Inc.


Send correspondence to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz
Agent for Applicants
Registration No. 48,181

RWE/ALS/lam
Enclosures

P:\USERS\Schwartz\Cases\1735\0610001\pto\nonprovptotm